Recent progress on tyrosine kinase 2 JH2 inhibitors

被引：7
|
作者：
Deng, Lidan [1 ]
Wan, Li [1 ]
Liao, Tingting [2 ]
Wang, Lin [3 ]
Wang, Jie [4 ]
Wu, Xianbo [1 ]
Shi, Jianyou [1 ,5 ,6 ,7 ]
机构：
[1] Chengdu Sport Univ, Sch Sports Med & Hlth, Chengdu 610041, Sichuan, Peoples R China
[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610072, Sichuan, Peoples R China
[3] Xihua Univ, Coll Food & Bioengn, Chengdu 610039, Peoples R China
[4] Guizhou Univ Tradit Chinese Med, Guiyang 550002, Guizhou, Peoples R China
[5] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Pharm,Sch Med, Personalized Drug Therapy Key Lab Sichuan Prov, Chengdu 610072, Sichuan, Peoples R China
[6] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Sichuan, Peoples R China
[7] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China
来源：
INTERNATIONAL IMMUNOPHARMACOLOGY | 2023年 / 121卷
基金：
中国国家自然科学基金;
关键词：
Tyrosine kinase 2 (TYK2); JH2; inhibitor; Autoimmune diseases; Deucravacitinib; BMS-986202; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PSORIATIC-ARTHRITIS; CLINICAL-FEATURES; JAK INHIBITORS; JANUS KINASES; IMMUNE; MECHANISMS; DISCOVERY; STATS; EPIDEMIOLOGY;
D O I：
10.1016/j.intimp.2023.110434
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family, which can regulate the signaling of multiple pro-inflammatory cytokines, including IL12, IL23 and type I interferon (IFN & alpha;/& beta;), and its inhibitors can treat autoimmune diseases caused by the abnormal expression of IL12 and IL23. Interest in TYK2 JH2 inhibitors has increased as a result of safety concerns with JAK inhibitors. This overview introduces TYK2 JH2 inhibitors that are already on the market, including Deucravactinib (BMS-986165), as well as those currently in clinical trials, such as BMS-986202, NDI-034858, and ESK-001.
引用
收藏
页数：10
相关论文
共 50 条
  • [21] Research progress in quinazoline derivatives as multi-target tyrosine kinase inhibitors
    Jin, Hao
    Dan, Hu-Guang
    Rao, Guo-Wu
    HETEROCYCLIC COMMUNICATIONS, 2018, 24 (01) : 1 - 10
  • [22] Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors
    Zhao, Xinge
    Huang, Wei
    Wang, Yazhou
    Xin, Minhang
    Jin, Qiu
    Cai, Jianfeng
    Tang, Feng
    Zhao, Yong
    Xiang, Hua
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (15) : 4344 - 4353
  • [23] Field-based 3D-QSAR for tyrosine protein kinase JAK-2 inhibitors
    Andole, Sowmya
    Thumma, Gouthami
    Alavala, Rajasekhar Reddy
    Gangarapu, Kiran
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (10) : 5321 - 5333
  • [24] Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
    Dhiwar, Prasad Sanjay
    Matada, Gurubasavaraja Swamy Purwarga
    Raghavendra, Nulgumnalli Manjunathaiah
    Ghara, Abhishek
    Singh, Ekta
    Abbas, Nahid
    Andhale, Ganesh Sakaram
    Shenoy, Ganesh Prasad
    Sasmal, Pujan
    MEDICINAL CHEMISTRY RESEARCH, 2022, 31 (09) : 1401 - 1413
  • [25] Analysis of Jak2 Catalytic Function by Peptide Microarrays: The Role of the JH2 Domain and V617F Mutation
    Sanz, Arturo
    Ungureanu, Daniela
    Pekkala, Tuija
    Ruijtenbeek, Rob
    Touw, Ivo P.
    Hilhorst, Riet
    Silvennoinen, Olli
    PLOS ONE, 2011, 6 (04):
  • [26] Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011-2013)
    Kethiri, Raghava R.
    Bakthavatchalam, Rajagopal
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (07) : 745 - 757
  • [27] TYROSINE-PROTEIN KINASE JAK2 INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
    Majumder, A.
    Sayeski, P. P.
    DRUGS OF THE FUTURE, 2010, 35 (08) : 651 - 660
  • [28] Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)
    Liu, Qingjie
    Batt, Douglas G.
    Lippy, Jonathan S.
    Surti, Neha
    Tebben, Andrew J.
    Muckelbauer, Jodi K.
    Chen, Lin
    An, Yongmi
    Chang, Chiehying
    Pokross, Matt
    Yang, Zheng
    Wang, Haiqing
    Burke, James R.
    Carter, Percy H.
    Tino, Joseph A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (19) : 4265 - 4269
  • [29] Tyrosine Kinase Inhibitors in Veterinary Medicine
    London, Cheryl A.
    TOPICS IN COMPANION ANIMAL MEDICINE, 2009, 24 (03) : 106 - 112
  • [30] Developing chemoresistance to tyrosine kinase inhibitors
    Smidova, Veronika
    Goliasova, Zita
    MENDELNET 2019: PROCEEDINGS OF 26TH INTERNATIONAL PHD STUDENTS CONFERENCE, 2019, : 632 - 635
12345